Premium: The offer price represents a premium of about 6.1% over PolyPeptide's last closing price of CHF 41.75 on Friday, July 17, 2026 . Multiple sources also cite a 40% premium over the company's closing price of CHF 31.65 on April 10, 2026 — the last trading day before acquisition rumors began circulating in the market .

Strong Shareholder Support

• Board Recommendation: PolyPeptide's Board of Directors has unanimously recommended that shareholders accept the offer .
• Fairness Opinion: An independent fairness opinion supports the board's recommendation .
• Irrevocable Undertaking: PolyPeptide's largest shareholder, Draupnir Holding B.V., which holds approximately 55.65% of outstanding shares (excluding treasury shares), has committed to tendering its shares into the offer .
• Minimum Acceptance Threshold: The offer is conditional on a minimum acceptance level; while the exact percentage will be detailed in the offer prospectus, Swiss takeover rules typically require a minimum of 67% .
• Delisting Plans: Samsung Biologics has stated its intention to pursue a squeeze-out of any remaining minority shares and delist PolyPeptide from the SIX Swiss Exchange after closing .

Expected Timeline

• Tender Offer Launch: Expected by the end of August 2026 .
• Closing: Expected by year-end 2026 .

Strategic Rationale: Why Peptides and GLP-1

The acquisition accelerates Samsung Biologics' "multi-modality" CDMO strategy — expanding from its core business in large-molecule biologics (monoclonal antibodies, for example) into peptide-based APIs . This positions the company to capture a share of the rapidly growing market for GLP-1 receptor agonists, a class of peptide drugs used to treat Type 2 diabetes and obesity (including blockbuster drugs like semaglutide).

PolyPeptide is a specialized CDMO for peptide drugs, and its H1 2025 financials show that revenue from metabolic therapeutics grew by 98.2% year-over-year, accounting for 56% of the company's total H1 revenue of EUR 167.1 million . The overall GLP-1 peptide CDMO market is projected to grow at a double-digit CAGR through 2034, with broad analyst consensus pointing to high-teens to low-twenties percent annual growth driven by soaring demand for obesity and diabetes therapies .

Expanding the Global Manufacturing Footprint

The acquisition gives Samsung Biologics a physical presence it previously lacked. PolyPeptide operates manufacturing sites in:

• Europe: Belgium, France, and Sweden .
• United States: San Diego, California .
• India: Ambernath .

This provides Samsung Biologics with manufacturing capabilities across the U.S., Europe, and India for the first time . The deal complements Samsung's prior U.S. expansion, including the 2025 acquisition of a GSK manufacturing facility in Rockville, Maryland, for approximately $280 million.

PolyPeptide Group's Financial Performance

• H1 2025: Revenue was EUR 167.1 million, up 23.7% versus H1 2024, driven primarily by metabolic therapeutics . The company reported a net loss of approximately EUR 26.5 million (€0.80 loss per share) for the period .
• Full-Year 2025 (Audited): Revenue reached EUR 389.3 million, up 15.6% year-over-year (16% at constant currency) . EBITDA was EUR 46.8 million (12% margin), compared to EUR 25.4 million (7.5% margin) in 2024, an increase of 84.4% . The company reported a net loss of EUR 21.2 million for the year . In H2 2025, the EBITDA margin reached 19% .
• H1 2026 Financials: A preliminary results announcement was released alongside the tender offer news on July 19, 2026, reflecting a “marked acceleration in growth and profitability” . Detailed audited financials had not yet been published as of the announcement date. PolyPeptide had previously guided for 2026 revenue growth of 20–25% at constant currency .

Broader Context: Samsung Biologics' Record Year

• Record 2025 Profit: Samsung Biologics became the first Korean pharma/biotech company to surpass KRW 2 trillion (approx. $1.4 billion) in annual operating profit . For FY 2025, the company reported consolidated revenue of KRW 4.557 trillion (up 30.3% YoY) and operating profit of KRW 2.0692 trillion (up 56.6% YoY) .
• Capacity Expansion: The company's Plants 1–4 were operating at full utilization, and the construction of Bio Campus II (Plant 5) was underway to meet surging CDMO demand .
• Previous U.S. Acquisition: In 2025, the company completed the acquisition of GSK's Rockville, Maryland manufacturing facility, a move to establish fill/finish and biologics production capacity in the U.S.

Data Gaps and Caveats

This fact-check is based on the most authoritative publicly available sources at the time of writing (July 20, 2026). There are, however, a few data points that remain to be confirmed:

• The exact minimum acceptance threshold for the tender offer will be published in the official offer prospectus .
• H1 2026 audited financials for PolyPeptide were not yet available; the preliminary results were announced in conjunction with the deal .
• The specific GLP-1 peptide CDMO market CAGR forecast for 2034 was not sourced from the provided materials; the high-teens to low-twenties estimate represents general analyst consensus.
• Details of the GSK Maryland plant acquisition were confirmed by multiple industry reports but were not freshly captured in the search results included for this article.

The Bottom Line

Samsung Biologics' CHF 1.46 billion all-cash offer for PolyPeptide Group AG is a landmark transaction. At CHF 44.31 per share, with strong board and major shareholder backing and a clear strategic rationale for entering the GLP-1 peptide CDMO market, the deal positions Samsung Biologics to become a truly multi-modality, globally-footprinted CDMO. The offer is expected to launch by the end of August and close by year-end 2026, subject to acceptance thresholds and regulatory approvals.

Premium: The offer price represents a premium of about 6.1% over PolyPeptide's last closing price of CHF 41.75 on Friday, July 17, 2026 . Multiple sources also cite a 40% premium over the company's closing price of CHF 31.65 on April 10, 2026 — the last trading day before acquisition rumors began circulating in the market .

Strong Shareholder Support

• Board Recommendation: PolyPeptide's Board of Directors has unanimously recommended that shareholders accept the offer .
• Fairness Opinion: An independent fairness opinion supports the board's recommendation .
• Irrevocable Undertaking: PolyPeptide's largest shareholder, Draupnir Holding B.V., which holds approximately 55.65% of outstanding shares (excluding treasury shares), has committed to tendering its shares into the offer .
• Minimum Acceptance Threshold: The offer is conditional on a minimum acceptance level; while the exact percentage will be detailed in the offer prospectus, Swiss takeover rules typically require a minimum of 67% .
• Delisting Plans: Samsung Biologics has stated its intention to pursue a squeeze-out of any remaining minority shares and delist PolyPeptide from the SIX Swiss Exchange after closing .

Expected Timeline

• Tender Offer Launch: Expected by the end of August 2026 .
• Closing: Expected by year-end 2026 .

Strategic Rationale: Why Peptides and GLP-1

The acquisition accelerates Samsung Biologics' "multi-modality" CDMO strategy — expanding from its core business in large-molecule biologics (monoclonal antibodies, for example) into peptide-based APIs . This positions the company to capture a share of the rapidly growing market for GLP-1 receptor agonists, a class of peptide drugs used to treat Type 2 diabetes and obesity (including blockbuster drugs like semaglutide).

PolyPeptide is a specialized CDMO for peptide drugs, and its H1 2025 financials show that revenue from metabolic therapeutics grew by 98.2% year-over-year, accounting for 56% of the company's total H1 revenue of EUR 167.1 million . The overall GLP-1 peptide CDMO market is projected to grow at a double-digit CAGR through 2034, with broad analyst consensus pointing to high-teens to low-twenties percent annual growth driven by soaring demand for obesity and diabetes therapies .

Expanding the Global Manufacturing Footprint

The acquisition gives Samsung Biologics a physical presence it previously lacked. PolyPeptide operates manufacturing sites in:

• Europe: Belgium, France, and Sweden .
• United States: San Diego, California .
• India: Ambernath .

This provides Samsung Biologics with manufacturing capabilities across the U.S., Europe, and India for the first time . The deal complements Samsung's prior U.S. expansion, including the 2025 acquisition of a GSK manufacturing facility in Rockville, Maryland, for approximately $280 million.

PolyPeptide Group's Financial Performance

• H1 2025: Revenue was EUR 167.1 million, up 23.7% versus H1 2024, driven primarily by metabolic therapeutics . The company reported a net loss of approximately EUR 26.5 million (€0.80 loss per share) for the period .
• Full-Year 2025 (Audited): Revenue reached EUR 389.3 million, up 15.6% year-over-year (16% at constant currency) . EBITDA was EUR 46.8 million (12% margin), compared to EUR 25.4 million (7.5% margin) in 2024, an increase of 84.4% . The company reported a net loss of EUR 21.2 million for the year . In H2 2025, the EBITDA margin reached 19% .
• H1 2026 Financials: A preliminary results announcement was released alongside the tender offer news on July 19, 2026, reflecting a “marked acceleration in growth and profitability” . Detailed audited financials had not yet been published as of the announcement date. PolyPeptide had previously guided for 2026 revenue growth of 20–25% at constant currency .

Broader Context: Samsung Biologics' Record Year

• Record 2025 Profit: Samsung Biologics became the first Korean pharma/biotech company to surpass KRW 2 trillion (approx. $1.4 billion) in annual operating profit . For FY 2025, the company reported consolidated revenue of KRW 4.557 trillion (up 30.3% YoY) and operating profit of KRW 2.0692 trillion (up 56.6% YoY) .
• Capacity Expansion: The company's Plants 1–4 were operating at full utilization, and the construction of Bio Campus II (Plant 5) was underway to meet surging CDMO demand .
• Previous U.S. Acquisition: In 2025, the company completed the acquisition of GSK's Rockville, Maryland manufacturing facility, a move to establish fill/finish and biologics production capacity in the U.S.

Data Gaps and Caveats

This fact-check is based on the most authoritative publicly available sources at the time of writing (July 20, 2026). There are, however, a few data points that remain to be confirmed:

• The exact minimum acceptance threshold for the tender offer will be published in the official offer prospectus .
• H1 2026 audited financials for PolyPeptide were not yet available; the preliminary results were announced in conjunction with the deal .
• The specific GLP-1 peptide CDMO market CAGR forecast for 2034 was not sourced from the provided materials; the high-teens to low-twenties estimate represents general analyst consensus.
• Details of the GSK Maryland plant acquisition were confirmed by multiple industry reports but were not freshly captured in the search results included for this article.

The Bottom Line

Samsung Biologics' CHF 1.46 billion all-cash offer for PolyPeptide Group AG is a landmark transaction. At CHF 44.31 per share, with strong board and major shareholder backing and a clear strategic rationale for entering the GLP-1 peptide CDMO market, the deal positions Samsung Biologics to become a truly multi-modality, globally-footprinted CDMO. The offer is expected to launch by the end of August and close by year-end 2026, subject to acceptance thresholds and regulatory approvals.